eligibility_summary
Eligible: adults (>18) with metastatic breast cancer (unresectable locally advanced, de novo stage IV, or recurrent metastatic) who plan to receive or have received sacituzumab govitecan monotherapy and have available medical history. Exclude: incomplete medical history, pregnancy, or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Observational, multi-center real‑world study in Chinese metastatic breast cancer patients receiving sacituzumab govitecan (10 mg/kg IV on days 1 and 8 of a 21‑day cycle). Drug/intervention: Sacituzumab govitecan (ADC, antibody‑drug conjugate). Mechanism: A humanized anti‑Trop‑2 monoclonal antibody delivers SN‑38 (active metabolite of irinotecan), a topoisomerase I inhibitor. After binding Trop‑2 on tumor cells, the ADC is internalized and SN‑38 is released, inhibiting topoisomerase I, causing DNA damage, S‑phase arrest, and apoptosis, a bystander effect can kill adjacent tumor cells. Targets: Trop‑2–expressing breast cancer cells, pathways include Trop‑2–mediated endocytosis and DNA replication/repair via topoisomerase I inhibition. Purpose: Evaluate real‑world effectiveness, safety, and potential predictors of response to sacituzumab govitecan.